IMO licensing in some specific jursidiction does not discourage a buy out, it might slightly lower the buy out price depending on the region licensed out as the acquiror will receive less of the value associated with that market.
But for example, China and Japan were specific local knowledge of the market is required for successful commercialisation, and also the need to run specific trials in those ethnic populations, means that quite often companies out-license assets in those markets. Some multi-national pharmas like AstraZeneca have pulled out of China altogether in favour of partnering with local companies.
If we were to license out bisantrene in CN or JP it wouldnt deter buyer's of the company or those interested in securing the rights to RoW.
If we were to start carving up the world with partnerships like DXB for example (different licensors in USA, EU, ME etc) then I think the chances of a buy out decline dramatically imo
RAC Price at posting:
$1.45 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)